Featured Publications
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sehested T, Bjerre J, Ku S, Chang A, Jahansouz A, Owens D, Hlatky M, Goldhaber-Fiebert J. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology 2019, 4: 128-135. PMID: 30649147, PMCID: PMC6439626, DOI: 10.1001/jamacardio.2018.4566.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioIncremental cost-effectiveness ratioRecurrent cardiovascular eventsHealth-related quality of lifeStandard of careCanakinumab Anti-inflammatory Thrombosis Outcomes StudyHs-CRP levelsLung cancer incidenceHealth-related qualityMyocardial infarctionCardiovascular eventsRate of recurrent MIHealth care sector perspectiveReduced all-cause mortalityQuality of lifeAll-cause mortalityCost-effectiveUS health care sector perspectiveHs-CRPCancer incidenceRisk of recurrent cardiovascular eventsMain OutcomesHigh-sensitivity C-reactive proteinSubstantial price reductions
2018
Patient and facility variation in costs of catheter ablation for atrial fibrillation
Perino A, Fan J, Schmitt S, Kaiser D, Heidenreich P, Narayan S, Wang P, Chang A, Turakhia M. Patient and facility variation in costs of catheter ablation for atrial fibrillation. Journal Of Cardiovascular Electrophysiology 2018, 29: 1081-1088. PMID: 29864193, PMCID: PMC6469652, DOI: 10.1111/jce.13655.Peer-Reviewed Original Research